Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Ultragenyx Pharmaceutical's Revenue for the
three
months ended in Mar. 2026 was MXN2,452 Mil. Ultragenyx Pharmaceutical's average Accounts Receivable for the
three
months ended in Mar. 2026 was MXN2,513 Mil.
Hence, Ultragenyx Pharmaceutical's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.98.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Ultragenyx Pharmaceutical Receivables Turnover Related Terms
Ultragenyx Pharmaceutical Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RARE vs VERA, IRON, QURE: Receivables Turnover Comparison
For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ultragenyx Pharmaceutical Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Ultragenyx Pharmaceutical's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical (MEX:RARE) has a Receivables Turnover of 0.98 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ultragenyx Pharmaceutical and its competitors. According to the industry distribution chart, Ultragenyx Pharmaceutical ranks #408 out of 841 companies in the Biotechnology industry, placing it in the top 48.5%.
Is Ultragenyx Pharmaceutical's Receivables Turnover too high?
Ultragenyx Pharmaceutical's current Receivables Turnover is 0.98. The Biotechnology industry median Receivables Turnover is 5.29. Ultragenyx Pharmaceutical's value of 0.98 is 81.5% below this industry median. Based on the distribution chart, Ultragenyx Pharmaceutical ranks #408 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Receivables Turnover compare to VERA and IRON?
According to the Biotechnology industry distribution chart, Ultragenyx Pharmaceutical ranks #408 out of 841 companies for Receivables Turnover. This puts Ultragenyx Pharmaceutical in the upper half of its industry. The industry median Receivables Turnover is 5.29. Ultragenyx Pharmaceutical's value of 0.98 is 81.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ultragenyx Pharmaceutical's current Receivables Turnover of 0.98 is 81.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ultragenyx Pharmaceutical and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ultragenyx Pharmaceutical's current Receivables Turnover is 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Ultragenyx Pharmaceutical (MEX:RARE) has a current Receivables Turnover of 0.98. The stock's GF Value™ is MXN1,861.65, compared to a current price of MXN1,150.56 — trading 38.2% below its estimated fair value. The current Receivables Turnover is 0.98 and 81.5% below the Biotechnology industry median of 5.29. Ultragenyx Pharmaceutical's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (MEX:RARE), the current Receivables Turnover is 0.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued.
The current stock price of MXN1,150.56 is trading 38.2% below its estimated GF Value™ of MXN1,861.65.
Key valuation signals for MEX:RARE:
Receivables Turnover: 0.98
GF Value™: MXN1,861.65 vs. price of MXN1,150.56 (38.2% below fair value)
Industry Position: 81.5% below the Biotechnology median (#408 of 841)
No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
69GF Score
Get the complete analysis for MEX:RARE
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RARE has been successfully added to your 
